报价延迟最少15分钟:2026/08/25 08:25 EDT
盘前时段
|
||||
|
190.93 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
190.74
|
|
|
| 价值评估 |
|
盈利(现时/预测)
3.31/13.41
|
|
企业价值
69.92B
|
| 资产负债 |
|
每股账面净值
89.64
|
| 现金流量 |
|
现金流量率
0.06
|
| 损益表 |
|
收益
21.84B
|
|
每股收益
69.92
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States. |
